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It is a truism in science that technical 
advances open the door for previously 
impossible scientific advances. This 
is evident in two articles from the 
laboratories of the late Jonathan 
Vogel, in which the investigators 
establish a reproducible orthotopic 
xenografting method for primary 
human cutaneous SCC tissue and 
cells and then use this method to 
demonstrate the existence of a long-
sought-after population of tumor-
initiating cells (TICs) in these tumors. 
These breakthrough studies stand as 
a triumphant monument to Vogel, 
who led these investigations and died 
30 October 2010.
Scc xenografting success at last
Whereas normal human skin can 
relatively easily be xenografted onto 
immunocompromised mice, the 
same cannot be said for cutaneous 
SCCs, and the inability to establish 
xenografts reliably from primary 
human SCCs has been a significant 
impediment for experimental studies 
of human SCCs in an in vivo setting. 
Although a number of labora tories 
have been able to establish several 
SCC cell lines that can be xenografted 
onto athymic mice (Tilgen et al., 
1983; Rheinwald and Beckett, 1981), 
the tumors produced tend to be poor-
ly differentiated; thus, comparing 
the biology and molecular genetics 
of different grades of human SCCs is 
difficult. An article published more 
than 10 years ago demonstrated the 
challenge: less than half of prema-
lignant skin lesions that engrafted 
on severe combined immunodefi-
cient (SCID), nude-SCID, or beige-
SCID mice contained human cells at 
the end of the study (Takizawa et al., 
1997). This was confirmed by Patel et 
al. (2012b, this issue), who report that 
only 2 of 22 human SCCs implanted 
by current methodology into any of 
these immuno compromised strains 
engrafted and formed a growing 
tumor.
The breakthrough by Patel et al. 
is based on the idea of humanizing 
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regenerating the hierarchical organization and histology of the original 
tumor through multiple xenograft passages.
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cleared mammary fat pads for 
xenografting human breast cancer 
cells. Using a prepared stromal graft 
bed for primary human SCC tis-
sue, or inclusion of primary nor-
mal fibroblasts within the prepared 
stromal bed and with the grafted 
single-cell suspensions, the authors 
achieved reliable high-frequency 
growth of xenografted primary SCC 
tissue and SCC single-cell suspen-
sions. Remarkably, xenografts from 
all tumor grades were successful, 
and the histology and growth char-
acteristics of the original tumors 
were maintained in the xenograft and 
through serial transplantation. Thus, 
this method overcomes issues of 
selection for more aggressive/malig-
nant clones and produces stable and 
reproducible tumor phenotypes.
Although the report highlights the 
importance of a highly vascularized 
reactive-tissue microenvironment for 
growth of primary human SCCs, it is 
not clear whether human fibroblasts 
are required for successful engraft-
ment of single-cell suspensions. It 
is possible that human fibroblasts 
provide the necessary survival fac-
tor or matrix component that mouse 
fibroblasts lack, or that human 
fibroblasts respond to the reactive 
stromal environment to acquire a 
cancer-associated fibroblast pheno-
type (Rasanen and Vaheri, 2010) that 
promotes tumor growth. Strikingly, 
xenografts grew reproducibly in athy-
mic nude mice, which lack T cells, 
but not in SCID-beige mice, which 
lack functional T, B, and natural killer 
cells, suggesting that some compo-
nent of the adaptive immune system 
acting either directly or through 
innate immune cells, such as neutro-
phils, mast cells, or other myeloid 
cells, is necessary for the growth 
of these tumor cells. This finding is 
intriguing because there is accumulat-
ing evidence that cells of the adaptive 
immune system can promote devel-
opment and progression of breast 
and squamous cancers. For example, 
gd T cells can protect against squa-
mous cancer, certain ab T-cell subsets 
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promote skin tumor progression 
(Girardi et al., 2003), and studies from 
the Coussens and Balkwill labs sug-
gest that B cells are important for the 
development of mouse skin tumors 
(de Visser et al., 2005; Schioppa et 
al., 2011). The results of Patel and col-
leagues’ studies (2012b) suggest that B 
cells are also important for the growth 
of human SCCs. This xenotransplanta-
tion model opens the door for studies 
on microenvironmental influences on 
the growth of human cutaneous SCCs.
Identifying the Scc tIc
Based on studies of leukemias, TICs 
(or cancer stem cells) in solid tumors 
are believed to constitute a small 
population of cells within the bulk 
of a tumor that have the capacity for 
long-term self-renewal. They are the 
only cells able to regenerate serially 
the hierarchical organization of pro-
liferating and differentiating compart-
ments in a xenograft model (Clevers, 
2011). Although these cells have 
been identified in several other solid-
tumor types, the lack of a xenograft 
model has so far precluded analysis 
in human cutaneous SCCs. With this 
methodological breakthrough, Patel 
and coworkers (2012a) were able to 
address the long-standing question 
of whether TICs exist in human cuta-
neous SCCs. The authors show that 
TICs in cutaneous SCCs are marked 
by CD133 (prominin) expression but 
not by other frequently used mark-
ers such as CD44 or CD34, a distinc-
tion from mouse skin TICs (Schober 
and Fuchs, 2011). TICs are present 
in the outer proliferative layer of 
SCC at a frequency of about 1 in 400 
cells. Unlike the bulk of SCCs that 
are CD133−, the CD133+ cells can 
generate an SCC that recapitulates 
the histology of the original tumor 
through serial passaging in athymic 
mice. Importantly, the frequency of 
CD133+ TICs does not increase with 
serial passaging, and CD133− cells 
cannot generate CD133+ cells. The 
low-frequency phenotype of the SCC 
TIC seems stable and does not exhibit 
the plasticity observed in some other 
xenograft models.
As with any breakthrough, many 
questions remain. One of the most 
striking observations made in the 
studies by Patel et al. is that the his-
tological phenotype of the cancer 
is a stable, passageable property of 
the TIC. Thus, the biochemical and 
genetic bases of these SCC pheno-
types are also probably controlled by 
the TICs, but they remain to be deter-
mined. Are well-differentiated and 
poorly differentiated SCCs derived 
from the same TICs with different 
genetic changes through clonal evo-
lution, or do they arise from different 
stem cell populations? Can CD133+ 
SCC cells be further subdivided by 
as-yet-unknown markers to identify 
cells more highly enriched for TIC 
properties? The relationship of the 
CD133+ TICs to CD133+ cells in the 
normal human epidermis and other 
epidermal stem cells also remains to 
be determined. Do SCCs that develop 
in organ-transplant recipients have 
TICs with properties distinct from 
those of spontaneous SCCs aris-
ing in a person with a functioning 
immune system? Most important, 
can therapies be designed that spe-
cifically target the TIC population, 
and could these be relevant for other 
epithelial tumors? With the develop-
ment of this xenograft method, these 
questions and many more are now 
accessible for experimental analysis.
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Clinical Implications
•  A small subpopulation of CD133+ cells within cutaneous squamous 
cell carcinomas (SCCs) have the inherent ability to generate the 
histology and organizational hierarchy of the original tumor and 
probably represent the tumor-initiating cell (TIC) or cancer stem cell.
•  The histological grade of an SCC is dependent, in an as-yet-undefined 
way, on the biochemical or genetic properties of the TIC.
• The SCC xenograft method represents the best in vivo approximation 
of human SCCs to test new drug therapies and to understand the 
molecular bases of cancer development.
